THE INACTIVATION OF THE GENE OF ARGININE DEIMINAZE OF STREPTOCOCCI REDUCES THE DEGREE OF THEIR ANTINEOPLASTIC ACTIVITY IN THE COURSE OF IN VITRO AND IN VIVO EXPERIMENTS



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Many bacteria, including Streptococcus pyogenes are able to suppress the development of tumors as at humans as at other mammals; however, mechanisms of the antitumor activity of bacteria are still unknown. Data about the role of the arginine deiminaze of streptococci as an important antitumor agent have been published. Purpose: in the present study the role of the arginine deiminaze in the antitumor activity of bacteria has been studied. Materials and methods: in course of performed studies the influence on the progress of tumors for cultures of two strains of Streptococcus pyogenes with the serotype M49 was compared: the M49-16 and M49-16delAD strains that produce the arginine deiminaze and that don’t produce it. In the first group of experiments performed in vitro, the culture of cells of hepatoma of 22a mice was affected by streptococci. Results: by means of the xCELLigence system (ACEA, USA), that makes possible to evaluate the condition of the culture of the tissue on a real-time basis it was shown that only streptococci that produce the arginine deiminaze have the cellulotoxic activity. During the second group of experiments performed on laboratory animals suffering with M37 sarcoma it was determined that the administration of streptococci that produce the arginine deiminaze into the tumor caused the decrease of the dimension of the tumor and as well as the decrease of the mortality of animals. The administration of streptococci that don’t produce this ferment did not have such effect.

Full Text

Restricted Access

About the authors

M A Suvorova

Institute of Experimental Medicine

T A Kramskaja

Institute of Experimental Medicine

A B Karaseva

Institute of Experimental Medicine

V N Mukhin

Institute of Experimental Medicine

E I Ermolenko

Institute of Experimental Medicine; St. Petersburg State University

A N Suvorov

Institute of Experimental Medicine; St. Petersburg State University

References

  1. Stewart B.W., Bray1 F., Forman D., Ohgaki H., Straif1 K., Ullrich A., Wild1 C. P. Cancer prevention as part of precision medicine: ‘plenty to be done’ // Carcinogenesis. 2016. Vol. 1. P. 2-9.
  2. Jessy T. Immunity over inability: the spontaneous regression of cancer // J. Nat Sci Biol Med. 2011. Vol. 2. P. 43-49.
  3. Nair N., Kasai T., Seno M. Bacteria: Prospective Savior in Battle against Cancer // Anticancer Res. 2014. Vol. 34, No 11. P. 6289-6296.
  4. Liu S., Xu X., Zeng X., Li L., Chen Q., Li J. Tumor-targeting bacterial therapy: A potential treatment for oral cancer // Oncology Letters. 2014. Vol. 6. P. 2359-2366.
  5. Maletzki C., Gock M., Klier U., Klar E., Linnebacher M. Bacteriolytic therapy of experimental pancreatic carcinoma // World J. Gastroenterol. 2010. Vol. 16, № 28. P. 3546-3552.
  6. Chen I.J., Yen C.F., Lin K.J., Lee C.L., Soong Y.K., Lai C.H., Lin C.T. Vaccination with OK-432 followed by TC-1 tumor lysate leads to significant antitumor effects // Reprod Sci. 2011. Vol. 7. P. 687-694.
  7. Maletzki C1., Emmrich J. Inflammation and immunity in the tumor environment // Dig Dis. - 2010. Vol. 28. P. 574-578.
  8. Hirayama M., Nishikawa H., Nagata Y., Tsuji T., Kato T., Kageyama S., Ueda S., Sugiyama D., Hori S., Sakaguchi S., Ritter G, Old LJ, Gnjatic S, Shiku H. Overcoming regulatory T-cell suppression by a lyophilized preparation of Streptococcus pyogenes // Eur J. Immunol. - 2013. Vol. 4. P. 989-1000.
  9. Lanuza G.A1., Bañón N.R., Llorca C.A., Delgado N.C. Unsuccessful treatment with OK-432 picibanil for orbital lymphangioma // Arch. Soc. Esp. Oftalmol. 2012. Vol. 1. P. 17-19.
  10. Kanaoka M., Kawanaka C., Negoro T., Fukita Y., Kiyoshi Т., Agui H. Cloning and Expression of the Anti tumor Glycoprotein Gene of Streptococcus pyogenes Su in Escherichia coli Masaharu Kanaoka // Agric. Biol. Chem. 1987. Vol. 10. P. 2641-2648.
  11. Dillon B.J., Prieto V.G., Curley SA, Ensor C.M., Holtsberg F.W., Bomalaski J.S. et al. Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation // Cancer. 2004. Vol. 7. P. 826-833.
  12. Suvorov A.N., Kok J., Venema G. Transformation of group A streptococci by electroporation // FEMS Microbiol. Lett. 1988. Vol. 56. P. 95-100.
  13. Cusumano Z.T., Caparon M.G. Citrulline Protects Streptococcus pyogenes from Acid Stress Using the Arginine Deiminase Pathway and the F1Fo-ATPase // J. Bacteriol. 2015. Vol. 197, No 7. P. 1288-1296.
  14. Cunin R. Glansdorff N., Piérard A., Stalon V. Biosynthesis and metabolism of arginine in bacteria // Microbiol Rev. 1986. Vol. 50, No 3. P. 314-352.
  15. Feun L., You M., Wu C.J., Kuo M.T., Wangpaichitr M., Spector S., Savara J.N. Arginine Deprivation as a Targeted Therapy for Cancer // Current Pharmaceutical Design. 2008. Vol. 14, № 11. P. 1049-1057.
  16. Ni Y., Schwaneberg U., Sun Z.-H. Arginine deiminase, a potential anti-tumor drug // Cancer Letters. 2008. Vol. 261, No 1. P. 1-11.
  17. Synakiewicz A., Stachowicz-Stencel T., Adamkiewicz-Drozynska E. The role of arginine and the modified arginine deiminase enzyme ADI-PEG 20 in cancer therapy with special emphasis on Phase I/II clinical trials // Expert Opinion on Investigational Drugs. 2014. Vol. 23, No 11. P. 1517-1529.
  18. Starikova E.A. et al. Biochemical and biological activity of arginine deiminase from Streptococcus pyogenes M22 // Biochem. Cell Biol. 2015. Vol. 94, No 2. P. 129-137.
  19. Старикова Э.А., Карасева А.Б., Бурова Л.А., Суворов А.Н., Соколов А.В., Васильев В.Б., Фрейдлин И.С. Роль аргининдеиминазы Sterprococcus pyogenes М49-16 в ингибиции пролифирации эндотелиальных клеток человека линии EA.hy926 // Медицинская иммунология. 2016. Т. 18 № 6. P. 559-566. [Starikova E., Karaseva A., Burova L., Suvorov A., Sokolov A., Vasilyev V., Freidlin J., Medical Immunology, 2016, vol. 18, No 6, рр. 559-566.].
  20. Fiedler T., Strauss M., Hering S., Redanz U., William D., Rosche Y., Classen CF., Kreikemeyer B., Linnebacher M., Maletzki C. Arginine deprivation by arginine deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo // Cancer Biol Ther. 2015. Vol. 7. P. 1047-1055.
  21. Yang W.S., Park S.O., Yoon A.R., Yoo J.Y., Kim M.K., Yun C.O., Kim C.W. Suicide cancer gene therapy using pore-forming toxin, streptolysin // Mol. Cancer Ther. 2006. Vol. 6. P. 1610-1619.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Suvorova M.A., Kramskaja T.A., Karaseva A.B., Mukhin V.N., Ermolenko E.I., Suvorov A.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.